Post-earnings recap
Reported
Thu, Nov 1, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Corvus Pharmaceuticals reported a loss of $0.36 per share, but the stock rose by 8.04% following the earnings announcement. The increase in stock price may indicate investor optimism despite the lack of revenue figures and guidance. The absence of detailed commentary from management leaves some uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.36 | N/A | — |
| Revenue | — | N/A | — |
No transcript is on record for the earnings call, so the analysis is based solely on numerical results.